Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 1-Year High – Should You Buy?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock price hit a new 52-week high on Thursday . The company traded as high as $22.54 and last traded at $22.37, with a volume of 3284248 shares trading hands. The stock had previously closed at $21.45.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Morgan Stanley cut their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Finally, JPMorgan Chase & Co. dropped their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Adaptive Biotechnologies Trading Up 4.3%

The firm has a market capitalization of $3.58 billion, a P/E ratio of -67.79 and a beta of 2.07. The business has a 50 day moving average of $15.81 and a 200-day moving average of $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. On average, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Francis Lo sold 39,741 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total value of $695,070.09. Following the sale, the insider directly owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the transaction, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. This trade represents a 41.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 698,316 shares of company stock valued at $11,655,488 over the last quarter. 5.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies in the first quarter worth $45,000. Assetmark Inc. boosted its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $51,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.